RXRX Recursion Pharmaceuticals Inc
Company Analysis
Latest News
🔴 Recursion Pharmaceuticals is trading 5.52% down today as U.S. equities retreat
Recursion Pharmaceuticals is trading 5.52% down at $3.25 as broad risk-off pressure weighs on U.S. equities. - The S&P 500 is down 0.45%, while the Nasdaq...
🔴 Recursion Pharmaceuticals is trading 5.37% down today amid broader risk-off trading
Recursion Pharmaceuticals is trading at $3.44 (-5.37%), with the decline appearing aligned with broader risk-off trading. - No clear company-specific...
🟢 Recursion Pharmaceuticals is trading 5% up today with no verified direct catalyst
Recursion Pharmaceuticals is trading $3.62 (+5.09%) with no verified direct catalyst identified. - No confirmed company-specific announcement or analyst...
🟢 Recursion Pharmaceuticals is trading 10% up today amid broad biotech-sector strength
Recursion Pharmaceuticals is trading at $3.58, up 10.00%, supported primarily by broad biotech-sector strength rather than a fresh company-specific...
🟢 Recursion Pharmaceuticals is trading 5% up today on biotech-sector strength
Recursion Pharmaceuticals is trading at $3.42, up 5.19%, mainly supported by biotech-sector strength. - No new company-specific announcement was identified on...
🟢 Recursion Pharmaceuticals is trading 5.39% up today with no clear company-specific catalyst identified
Recursion Pharmaceuticals is trading $3.52, up 5.39%, with no clearly identified company-specific catalyst on August 21, 2026. - No new company announcement...
🔴 Recursion Pharmaceuticals falls 5.1% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🔴 Recursion Pharmaceuticals is trading 5.17% down in pre-market — no clear company-specific catalyst identified
Recursion Pharmaceuticals is trading 5.17% down at $3.32, with no clear company-specific catalyst identified. - The decline reverses part of the August 19,...
🟢 Recursion Pharmaceuticals is trading 10.36% up today after positive Phase 3 melanoma cancer-vaccine results
Recursion Pharmaceuticals is trading 10.36% up at $3.41, mainly as biotech stocks rallied after positive Phase 3 melanoma cancer-vaccine results from Moderna...
🟢 Recursion Pharmaceuticals rises 5.0% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
🔴 Recursion Pharmaceuticals is trading 5.63% down today as higher Treasury yields pressure technology stocks
Recursion Pharmaceuticals is trading 5.63% down now at $2.92 as technology stocks weaken amid rising Treasury yields, oil prices, and renewed U.S.-Iran...
Recursion's second quarter shows pipeline progress with a Genentech milestone and reduced FY2026 expense guidance despite a revenue miss.
Recursion Pharmaceuticals reported second quarter 2026 revenue of $7.7 million, missing analyst estimates, while its EPS loss of $0.25 was in line with...
🟢 Recursion Pharmaceuticals is trading 5% up today ahead of Q2 earnings and a broader biotech rally
Recursion Pharmaceuticals is trading 5% up at $3.35 as investors position themselves ahead of the company's second-quarter results scheduled for August 5,...
Recursion Pharmaceuticals Inc Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
Analysts expect Recursion Pharmaceuticals to report a Q2 2026 consensus revenue of $10.97 million and an EPS loss of $0.25, with the stock currently trading...
🟢 Recursion Pharmaceuticals is trading 5.2% up today amid a broader market rally
Recursion Pharmaceuticals is trading 5.2% up at $3.15 today, tracking a broader market rally as major indices gain more than 1%. • The move comes amid a...
🟢 Recursion Pharmaceuticals is trading 5.2% up today on a technical rebound from recent weakness
Recursion Pharmaceuticals is trading 5.2% up today at $3.04 as the stock stages a modest rebound from recent weakness despite a lack of fresh company-specific...
Recursion Pharma Stock Slides After Insider Files Intent to Sell Shares
Recursion Pharmaceuticals (NASDAQ: RXRX) shares fell more than 7% on Thursday, July 16. An insider filed a Form 144 with the SEC. The filing indicated an...
AI Drug Discovery Faces Investor Reality Check Over Long Timelines
Investor skepticism is growing over the timeline for returns from AI in drug discovery, creating a disconnect with Wall Street's expectations. [1, 5] While AI...
🔴 Recursion Pharmaceuticals is trading 5.1% down today with no clear catalyst
Recursion Pharmaceuticals is trading at $3.14 (5.1% down) today amid a lack of fresh, company-specific news or major announcements directly tied to the...
🔴 Recursion Pharmaceuticals is trading 5.1% down today amid a broader biotech sector pullback
Recursion Pharmaceuticals is trading at $3.38 (5.1% down) amid a broader pullback in high-beta biotech and risk assets. • The move aligns with a decline in...